Australia Health

Paradigm Biopharmaceuticals (ASX:PAR) appointed Dr Daniel Furtner as chief medical officer, effective Sept. 16.

Mayne Pharma (ASX:MYX) secured exclusive five-year Australian rights to commercialise menopause gel Blissel.

Entropy Neurodynamics (ASX:ENP) reported positive Phase 2 trial results for its intravenous psilocin drug TRP-8803.

HealthCo Healthcare & Wellness REIT (ASX:HCW) and the Unlisted Healthcare Fund secured lender support to transfer operations across 10 hospitals to alternative operators.

Dimerix (ASX:DXB) was granted a composition of matter patent in Mexico for its clinical-stage asset, DMX-652.

Telix Pharmaceuticals (ASX:TLX) received official approval from the U.S. Food and Drug Administration for its brain cancer imaging agent Pixclara.

Immutep (ASX:IMM) has contracted a new 200-litre manufacturing run of eftilagimod alfa following the early discontinuation of its TACTI-004 clinical study.

Optiscan Imaging (ASX:OIL) imaged over 80 cases using its InForm platform in a live digital pathology study conducted with Australian Clinical Labs.

Lenders for Healthscope have extended a crucial vote by 24 hours to decide on a takeover offer exceeding $400 million for 27 hospital sites.

Biome Australia (ASX:BIO) announced it will launch Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60 in the first half of FY27.

Neurizon Therapeutics (ASX:NUZ) announced that the US National Institutes of Health awarded a multi-year grant.

Osteopore (ASX:OSX) secured market access in Thailand for its complete line of orthopaedic products.